{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T03:20:02Z","timestamp":1794453602553,"version":"4.9.1"},"reference-count":64,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The French Journal of Urology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.fjurol.2025.102962","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T18:26:08Z","timestamp":1757096768000},"page":"102962","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Oral drug treatments of erectile dysfunction: A AFU\/SFMS systematic review"],"prefix":"10.1016","volume":"35","author":[{"given":"Ala","family":"Chebbi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6056-4906","authenticated-orcid":false,"given":"Hugo","family":"Dupuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6671-1863","authenticated-orcid":false,"given":"Diana","family":"Kassab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Burte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9445-4385","authenticated-orcid":false,"given":"Eric","family":"Huyghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovic","family":"Ferretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.fjurol.2025.102962_bib0330","unstructured":"ICD-11. The International Classification of Diseases and Related Health Problems, Eleventh Revision (ICD-11) - https:\/\/icd.who.int\/browse\/2024-01\/mms\/fr#97556145. 2024."},{"key":"10.1016\/j.fjurol.2025.102962_bib0335","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0090-4295(02)02102-7","article-title":"Epidemiology of erectile dysfunction in four countries: cross-national study of the prevalence and correlates of erectile dysfunction","volume":"61","author":"Nicolosi","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.fjurol.2025.102962_bib0340","first-page":"1011","article-title":"[Recommendations to general practice doctors for first line management of erectile dysfunction]","volume":"15","author":"Cour","year":"2005","journal-title":"Prog Urol"},{"key":"10.1016\/j.fjurol.2025.102962_bib0345","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.sexol.2010.12.009","article-title":"Guidelines for general practitioners for first-line management of erectile dysfunction (updated 2010)","volume":"20","author":"Cuzin","year":"2011","journal-title":"Sexologies"},{"key":"10.1016\/j.fjurol.2025.102962_bib0350","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.purol.2013.01.010","article-title":"[Erectile dysfunction]","volume":"23","author":"Giuliano","year":"2013","journal-title":"Prog Urol"},{"key":"10.1016\/j.fjurol.2025.102962_bib0355","first-page":"583","article-title":"[Erectile dysfunction: up-date data and clinical guidelines]","volume":"15","author":"Colson","year":"2019","journal-title":"Rev Med Suisse"},{"key":"10.1016\/j.fjurol.2025.102962_bib0360","doi-asserted-by":"crossref","first-page":"102842","DOI":"10.1016\/j.fjurol.2024.102842","article-title":"Therapeutic management of erectile dysfunction: the AFU\/SFMS guidelines","volume":"35","author":"Huyghe","year":"2024","journal-title":"Fr J Urol"},{"key":"10.1016\/j.fjurol.2025.102962_bib0365","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1007\/s12325-020-01559-9","article-title":"Vardenafil in the treatment of male erectile dysfunction: a systematic review and meta-analysis","volume":"38","author":"Wang","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.fjurol.2025.102962_bib0370","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s00345-020-03233-9","article-title":"Efficacy and safety of oral phosphodiesterase 5 inhibitors for erectile dysfunction: a network meta-analysis and multicriteria decision analysis","volume":"39","author":"Madeira","year":"2021","journal-title":"World J Urol"},{"key":"10.1016\/j.fjurol.2025.102962_bib0375","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.esxm.2019.06.006","article-title":"Meta-analysis of the long-term efficacy and tolerance of tadalafil daily compared with tadalafil on-demand in treating men with erectile dysfunction","volume":"7","author":"Zhou","year":"2019","journal-title":"Sex Med"},{"key":"10.1016\/j.fjurol.2025.102962_bib0380","doi-asserted-by":"crossref","DOI":"10.1177\/1557988319880764","article-title":"Avanafil for the treatment of men with erectile dysfunction: a systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Li","year":"2019","journal-title":"Am J Mens Health"},{"key":"10.1016\/j.fjurol.2025.102962_bib0385","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.urology.2017.08.031","article-title":"The efficacy of tadalafil daily vs on demand in the treatment of erectile dysfunction: a systematic review and meta-analysis","volume":"112","author":"Bansal","year":"2018","journal-title":"Urology"},{"key":"10.1016\/j.fjurol.2025.102962_bib0390","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1111\/ijcp.12976","article-title":"Quality of erections by age group in men with erectile dysfunction","volume":"71","author":"Kaminetsky","year":"2017","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.fjurol.2025.102962_bib0395","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1007\/s11255-017-1644-5","article-title":"Direct comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review and meta-analysis","volume":"49","author":"Gong","year":"2017","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.fjurol.2025.102962_bib0400","doi-asserted-by":"crossref","first-page":"60","DOI":"10.4103\/1008-682X.154304","article-title":"A meta-regression evaluating the effectiveness and prognostic factors of oral phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction","volume":"18","author":"Yuan","year":"2016","journal-title":"Asian J Androl"},{"key":"10.1016\/j.fjurol.2025.102962_bib0405","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.jsxm.2016.02.166","article-title":"Efficacy and safety of sildenafil by age in men with erectile dysfunction","volume":"13","author":"Goldstein","year":"2016","journal-title":"J Sex Med"},{"key":"10.1016\/j.fjurol.2025.102962_bib0410","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.eururo.2015.03.031","article-title":"Phosphodiesterase 5 inhibitors for the treatment of erectile dysfunction: a trade-off network meta-analysis","volume":"68","author":"Chen","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2025.102962_bib0415","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1185\/03007995.2014.909391","article-title":"The effectiveness and safety of avanafil for erectile dysfunction: a systematic review and meta-analysis","volume":"30","author":"Wang","year":"2014","journal-title":"Curr Med Res Opinion"},{"key":"10.1016\/j.fjurol.2025.102962_bib0420","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.eururo.2013.09.037","article-title":"Tadalafil once daily in men with erectile dysfunction: an integrated analysis of data obtained from 1913 patients from six randomized, double-blind, placebo-controlled, clinical studies","volume":"65","author":"Porst","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2025.102962_bib0425","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.eururo.2013.01.012","article-title":"Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis","volume":"63","author":"Yuan","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2025.102962_bib0430","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1742-1241.2009.02254.x","article-title":"Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database","volume":"64","author":"Giuliano","year":"2010","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.fjurol.2025.102962_bib0435","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/sj.ijir.3901258","article-title":"Vardenafil (Levitra) for erectile dysfunction: a systematic review and meta-analysis of clinical trial reports","volume":"16","author":"Markou","year":"2004","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.fjurol.2025.102962_bib0440","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/iju.14785","article-title":"Efficacy and safety of avanafil as compared with sildenafil in the treatment of erectile dysfunction: A randomized, double blind, multicenter clinical trial","volume":"29","author":"Kumar","year":"2022","journal-title":"Int J Urol"},{"key":"10.1016\/j.fjurol.2025.102962_bib0445","doi-asserted-by":"crossref","first-page":"100337","DOI":"10.1016\/j.esxm.2021.100337","article-title":"Efficacy and safety of avanafil in Chinese subjects with erectile dysfunction: a multi-center, randomized, double-blinded, placebo-controlled phase III clinical trial","volume":"9","author":"Jiang","year":"2021","journal-title":"Sex Med"},{"key":"10.1016\/j.fjurol.2025.102962_bib0450","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/jsm.12818","article-title":"Treatment satisfaction of men and partners following switch from on-demand phosphodiesterase type 5 inhibitor therapy to tadalafil 5\u00a0mg once daily","volume":"12","author":"Burns","year":"2015","journal-title":"J Sex Med"},{"key":"10.1016\/j.fjurol.2025.102962_bib0455","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJM199805143382001","article-title":"Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group","volume":"338","author":"Goldstein","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fjurol.2025.102962_bib0460","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/ijir.2014.39","volume":"27","author":"Shin","year":"2015","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.fjurol.2025.102962_bib0465","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/ijcp.12449","article-title":"Continuation and effectiveness of tadalafil once daily during a 6-month observational study in erectile dysfunction: the EDATE study","volume":"68","author":"Buvat","year":"2014","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.fjurol.2025.102962_bib0470","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1111\/j.1743-6109.2011.02352.x","article-title":"Improvement in sexual quality of life of the female partner following vardenafil treatment of men with erectile dysfunction: a randomized, double-blind, placebo-controlled study","volume":"8","author":"Mart\u00edn-Morales","year":"2011","journal-title":"J Sex Med"},{"key":"10.1016\/j.fjurol.2025.102962_bib0475","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/j.1743-6109.2011.02629.x","article-title":"A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction","volume":"9","author":"Goldstein","year":"2012","journal-title":"J Sex Med"},{"key":"10.1016\/j.fjurol.2025.102962_bib0480","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1111\/j.1464-410X.2012.11095.x","article-title":"Efficacy and safety of avanafil for treating erectile dysfunction: results of a multicentre, randomized, double-blind, placebo-controlled trial","volume":"110","author":"Zhao","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.fjurol.2025.102962_bib0485","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.juro.2010.09.035","article-title":"Onset of efficacy of tadalafil once daily in men with erectile dysfunction: a randomized, double-blind, placebo controlled trial","volume":"185","author":"Seftel","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2025.102962_bib0490","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1210\/jc.2017-02389","article-title":"Randomized trial of CPAP and vardenafil on erectile and arterial function in men with obstructive sleep apnea and erectile dysfunction","volume":"103","author":"Melehan","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.fjurol.2025.102962_bib0495","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1530\/EJE-15-1100","article-title":"Six months of daily treatment with vardenafil improves parameters of endothelial inflammation and of hypogonadism in male patients with type 2 diabetes and erectile dysfunction: a randomized, double-blind, prospective trial","volume":"174","author":"Santi","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.fjurol.2025.102962_bib0500","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/andr.12079","article-title":"An integrated approach with vardenafil orodispersible tablet and cognitive behavioral sex therapy for treatment of erectile dysfunction: a randomized controlled pilot study","volume":"3","author":"Boddi","year":"2015","journal-title":"Andrology"},{"key":"10.1016\/j.fjurol.2025.102962_bib0505","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1111\/jsm.12496","volume":"11","author":"Martin-Morales","year":"2014","journal-title":"J Sex Med"},{"key":"10.1016\/j.fjurol.2025.102962_bib0510","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/sj.ijir.3900713","article-title":"The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial","volume":"13","author":"Porst","year":"2001","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.fjurol.2025.102962_bib0515","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/j.1939-4640.2002.tb02332.x","article-title":"Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial","volume":"23","author":"Hellstrom","year":"2002","journal-title":"J Androl"},{"key":"10.1016\/j.fjurol.2025.102962_bib0520","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2337\/diacare.26.3.777","article-title":"Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study","volume":"26","author":"Goldstein","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.fjurol.2025.102962_bib0525","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.eururo.2006.02.052","article-title":"Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5mg and 10mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"50","author":"Porst","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2025.102962_bib0530","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/sj.ijir.3901496","article-title":"Tadalafil dosed once a day in men with erectile dysfunction: a randomized, double-blind, placebo-controlled study in the US","volume":"19","author":"Rajfer","year":"2007","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.fjurol.2025.102962_bib0535","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1464-5491.2007.02338.x","article-title":"Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction","volume":"25","author":"Hatzichristou","year":"2008","journal-title":"Diabet Med"},{"key":"10.1016\/j.fjurol.2025.102962_bib0540","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1111\/j.1743-6109.2009.01222.x","article-title":"Impact on erectile function and sexual quality of life of couples: a double-blind, randomized, placebo-controlled trial of tadalafil taken once daily","volume":"6","author":"Rubio-Aurioles","year":"2009","journal-title":"J Sex Med"},{"key":"10.1016\/j.fjurol.2025.102962_bib0545","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1111\/j.1743-6109.2011.02353.x","article-title":"A randomized, double-blind, placebo-controlled, parallel study to assess the efficacy and safety of once-a-day tadalafil in men with erectile dysfunction who are na\u00efve to PDE5 inhibitors","volume":"8","author":"Montorsi","year":"2011","journal-title":"J Sex Med"},{"key":"10.1016\/j.fjurol.2025.102962_bib0550","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1743-6109.2011.02504.x","article-title":"Tadalafil 2.5 or 5mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study","volume":"9","author":"Egerdie","year":"2012","journal-title":"J Sex Med"},{"key":"10.1016\/j.fjurol.2025.102962_bib0555","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1743-6109.2005.20360.x","article-title":"Comparison of efficacy, safety, and tolerability of on-demand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction","volume":"2","author":"McMahon","year":"2005","journal-title":"J Sex Med"},{"key":"10.1016\/j.fjurol.2025.102962_bib0560","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1111\/j.1743-6109.2010.01890.x","article-title":"Efficacy and safety of tadalafil 20mg on demand vs. tadalafil 5mg once-a-day in the treatment of post-radiotherapy erectile dysfunction in prostate cancer men: a randomized phase II trial","volume":"7","author":"Ricardi","year":"2010","journal-title":"J Sex Med"},{"key":"10.1016\/j.fjurol.2025.102962_bib0565","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/j.1742-1241.2012.02946.x","article-title":"Comparison of efficacy for erectile function and lower urinary tract symptoms of tadalafil 20\u00a0mg on-demand and 5\u00a0mg once daily in patients with erectile dysfunction","volume":"66","author":"Kang","year":"2012","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.fjurol.2025.102962_bib0570","first-page":"1195","article-title":"Evaluation of the efficacy of once-daily use of tadalafil vs. on-demand use. Is there a cumulative effect?","volume":"62","author":"Jamshidian","year":"2012","journal-title":"JPMA"},{"key":"10.1016\/j.fjurol.2025.102962_bib0575","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1111\/j.1743-6109.2012.02667.x","article-title":"A randomized open-label trial with a crossover comparison of sexual self-confidence and other treatment outcomes following tadalafil once a day vs. tadalafil or sildenafil on-demand in men with erectile dysfunction","volume":"9","author":"Rubio-Aurioles","year":"2012","journal-title":"J Sex Med"},{"key":"10.1016\/j.fjurol.2025.102962_bib0580","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.eururo.2013.09.051","article-title":"Effects of tadalafil treatment on erectile function recovery following bilateral nerve-sparing radical prostatectomy: a randomised placebo-controlled study (REACTT)","volume":"65","author":"Montorsi","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2025.102962_bib0590","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.mayocp.2012.06.016","article-title":"Avanafil for the treatment of erectile dysfunction: a multicenter, randomized, double-blind study in men with diabetes mellitus","volume":"87","author":"Goldstein","year":"2012","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.fjurol.2025.102962_bib0595","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/ijcp.12065","article-title":"An open-label, long-term evaluation of the safety, efficacy and tolerability of avanafil in male patients with mild to severe erectile dysfunction","volume":"67","author":"Belkoff","year":"2013","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.fjurol.2025.102962_bib0600","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1016\/j.juro.2012.11.177","article-title":"A phase 3, placebo controlled study of the safety and efficacy of avanafil for the treatment of erectile dysfunction after nerve sparing radical prostatectomy","volume":"189","author":"Mulhall","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2025.102962_bib0605","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.clinthera.2010.06.011","article-title":"Tolerability and pharmacokinetics of avanafil, a phosphodiesterase type 5 inhibitor: a single- and multiple-dose, double-blind, randomized, placebo-controlled, dose-escalation study in healthy Korean male volunteers","volume":"32","author":"Jung","year":"2010","journal-title":"Clin Ther"},{"key":"10.1016\/j.fjurol.2025.102962_bib0610","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.juro.2014.12.101","article-title":"Efficacy of avanafil 15 minutes after dosing in men with erectile dysfunction: a randomized, double-blind, placebo controlled study","volume":"194","author":"Hellstrom","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2025.102962_bib0615","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.3346\/jkms.2017.32.6.1016","article-title":"A randomized, placebo-controlled, double-blind, multi-center therapeutic confirmatory study to evaluate the safety and efficacy of avanafil in korean patients with erectile dysfunction","volume":"32","author":"Park","year":"2017","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.fjurol.2025.102962_bib0620","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0140-6736(87)90958-5","article-title":"Double-blind trial of yohimbine in treatment of psychogenic impotence","volume":"2","author":"Reid","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.fjurol.2025.102962_bib0625","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/S0022-5347(17)41308-5","article-title":"Effect of yohimbine hydrochloride on erectile impotence: a double-blind study","volume":"141","author":"Susset","year":"1989","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2025.102962_bib0630","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S0022-5347(01)64032-1","article-title":"Therapeutic effects of high dose yohimbine hydrochloride on organic erectile dysfunction","volume":"159","author":"Tel\u00f6ken","year":"1998","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2025.102962_bib0635","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/S0302-2838(02)00175-6","article-title":"Efficacy and safety of a novel combination of L-arginine glutamate and yohimbine hydrochloride: a new oral therapy for erectile dysfunction","volume":"41","author":"Lebret","year":"2002","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2025.102962_bib0640","first-page":"1","article-title":"Efficacy and safety of oral combination of yohimbine and l-arginine (SX) for the treatment of erectile dysfunction: a multicenter, randomized, double blind, placebo-controlled clinical trial","volume":"5","author":"Akhondzadeh","year":"2010","journal-title":"Iran J Psychiatry"},{"key":"10.1016\/j.fjurol.2025.102962_bib0645","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S0090-4295(94)80216-5","article-title":"Effect of yohimbine-trazodone on psychogenic impotence: a randomized, double-blind, placebo-controlled study","volume":"44","author":"Montorsi","year":"1994","journal-title":"Urology"},{"key":"10.1016\/j.fjurol.2025.102962_bib0650","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/jsxmed\/qdad163","article-title":"Princeton IV consensus guidelines: PDE5 inhibitors and cardiac health","volume":"21","author":"Kloner","year":"2024","journal-title":"J Sex Med"}],"container-title":["The French Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950393025001093?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950393025001093?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:46:57Z","timestamp":1790178417000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950393025001093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":64,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2950393025001093"],"URL":"https:\/\/doi.org\/10.1016\/j.fjurol.2025.102962","relation":{},"ISSN":["2950-3930"],"issn-type":[{"value":"2950-3930","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral drug treatments of erectile dysfunction: A AFU\/SFMS systematic review","name":"articletitle","label":"Article Title"},{"value":"The French Journal of Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.fjurol.2025.102962","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"102962"}}